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The Erb-B family of receptors plays an important role in the development and therapyof non-small cell lung cancer (NSCLC).1 Most of the interest has been devoted to the
epidermal growth factor receptor (EGFR) due to the favorable clinical effect of the EGFR
targeted therapies, especially demonstrated for the EGFR tyrosine kinase inhibitors (TKIs)
erlotinib (Tarceva) and gefitinib (IRESSA).2,3 The monoclonal antibodies (e.g., cetuximab
[Erbitux]) demonstrated effect in nonpulmonary malignancies such as colorectal cancer
and head and neck cancer.4,5
Erlotinib (Tarceva) demonstrated survival benefit in unselected NSCLC patients
who previously failed on chemotherapy, but 30% of patients in each arm died by 4
months, and the overall survival advantage was modest.6 Thus, the challenge is to identify
the patients who will or will not benefit from the EGFR inhibitors. Clinical parameters are
insufficient for the selection of patients to receive EGFR inhibitors because some survival
benefit is also seen in “nonfavorable” subgroups (e.g., in males, those with squamous cell
carcinomas, and ever smokers).7,8 Therefore, the search for molecular biomarkers that can
be used to predict the clinical outcome of EGFR targeted therapy has become crucial.
Molecular biomarkers that can be used for prognostication in general and for the
prediction of the clinical outcome with EGFR inhibitors in particular include EGFR gene
copy number detected by fluorescence in situ hybridization (FISH)7–10 EGFR mutations in
the tyrosine kinase domain detected by DNA sequencing,11,12 and EGFR protein expres-
sion assessed by immunohistochemistry.7,8,10
EGFR DNA polymorphisms are another potential molecular marker. One of the
enhancer elements for EGFR is located in intron 1, and EGFR transcription may be
prematurely terminated in intron 1.13,14 A well-described dinucleotide CA repeat sequence
polymorphism in intron 1 of EGFR ranges from 14 to 22 repeats, with the most common
allele being 16 repeats. The shorter alleles (16 repeats) are associated with greater EGFR
expression compared with the longer repeats.15,16
In this issue of Journal of Thoracic Oncology, Dubey et al.17 reported that EGFR
dinucleotide repeat polymorphism is a good prognostic indicator in NSCLC based on the
results from the Eastern Cooperative Oncology Group 3590 adjuvant trial, in which
patients received adjuvant radiotherapy (RT) or RT plus chemotherapy. The overall
survival was similar in both arms.18 However, subanalysis demonstrated that patients with
EGFR intron 1 polymorphism having 35 CA repeats had a significantly longer overall
survival with a median survival of 41 months compared with 29.2 months for the patients
with the sum of alleles (CA)n 35. However, there was no difference in median survival
between the two groups of patients for those who received RT alone, but a difference in
median survival was seen between the groups in the RT plus chemotherapy group.
Although the median survival in the two groups (RT or RT plus chemotherapy) was about
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40 months, the median survival for patients with 35 (CA)n
was 25.3 months in the short allele group, indicating a shorter
survival compared with the other groups. Thus, the EGFR
dinucleotide repeat polymorphism could be interpreted as a
nonfavorable predictive marker associated with the combined
treatment of RT plus chemotherapy.
WHEN IS A BIOMARKER PROGNOSTIC AND
WHEN IS IT PREDICTIVE OF THE CLINICAL
OUTCOME OF A GIVEN THERAPY?
Some confusion exists in the literature regarding
whether biomarkers are prognostic and/or predictive. A prog-
nostic marker is a patient characteristic or a tumor factor that
predicts outcome (usually survival) independent of treatment
administered. A predictive marker is a clinical or molecular
marker that predicts outcome of a specific treatment (either in
terms of tumor shrinkage or survival from the particular
therapy).
Is EGFR polymorphism in intron 1 a prognostic or
predictive marker for the given therapy, in this case, RT with
or without chemotherapy? Unfortunately, we are not aware of
studies in NSCLC patients who are treated with surgery alone
that could tell whether EGFR polymorphism is a prognostic
marker per se. In the subanalysis results from the Eastern
Cooperative Oncology Group study 3590, there was no dif-
ference in median survival between the group with 35
dinucleotide repeats and those with 35 repeats in the RT
arm, and no difference compared with the median survival in
the whole study, but a difference in survival was reported in
the RT plus chemotherapy arm (median, 40.9 versus 25.3
months). The authors conclude that EGFR dinucleotide poly-
morphisms (35 CA nucleotide repeats) are a good prognos-
tic marker. However, it appears that CA repeats 35 with a
median survival of 25 months is a negative predictive marker
for the combination of RT and chemotherapy, especially
when the overall median survival in the study is about 40
months.17
The study did not address the use of dinucleotide
repeats for predicting benefit from EGFR TKIs, which should
be examined in future studies. In the past, several “predic-
tive” markers for clinical outcome after EGFR inhibitors have
been reported. Activating mutations in the EGFR tyrosine
kinase domain in exons 18 to 21 were identified as the first
marker of better clinical outcome to EGFR TKIs in NSCLC
patients.11,12 The discovery of specific EGFR mutations as-
sociated with sensitivity to EGFR TKIs was significant and
provided new insight into the mechanisms of the sensitivity to
these drugs. Furthermore, it sparked and focused the research
in this field. However, although there is consistency in the
data showing a strong association between specific EGFR
mutations and response to EGFR TKIs in advanced NSCLC,
the association with prolonged survival in the Western pop-
ulation is still debated. Furthermore, in studies of NSCLC
patients treated with chemotherapy with or without EGFR
TKIs, the patients with EGFR mutations fared better than
those without mutations, irrespective of therapy, which indi-
cates a more indolent biological course of the EGFR-mutated
tumors.19,20 Thus, the EGFR mutations seem to have a prog-
nostic impact, which was also demonstrated in surgically
resected patients in the study of Shigematsu et al..21 However,
there might be differences in the prognostic/predictive impact
of the different subgroups of EGFR mutations, which needs
to be further elucidated in future prospective studies.22,23
The most consistent EGFR marker associated with
survival after treatment with EGFR TKIs in the Western
population is the EGFR gene copy number detected by FISH.
A legitimate question is whether this “marker” is also prog-
nostic? Several studies have elucidated the prognostic aspects
of EGFR FISH.
We published a study of the prognostic value of EGFR
immunohistochemistry and FISH in NSCLC patients who
underwent surgical resection. Although not statistically sig-
nificant, there was a trend toward shorter survival for the
EGFR FISH–positive patients.24 In the recently presented
randomized trial (IRESSA Survival Evaluation in Lung Can-
cer [ISEL] trial), in which patients were randomized to
gefitinib or placebo, the FISH-positive patients who received
placebo fared more poorly (median survival, 4.5 months) than
the FISH-negative patients (median survival, 6.5 months),
indicating a less favorable outcome associated with increased
EGFR gene copy number detected by FISH.7 We are cur-
rently studying the association between increased EGFR gene
copy number and clinical outcome after chemotherapy alone.
Preliminary results show no difference in the outcome be-
tween the FISH-positive and FISH-negative groups.25
The prognostic and predictive role of EGFR protein
expression has been debated. Some studies including a meta-
analysis have shown that EGFR protein expression assessed
by immunohistochemistry is a poor prognostic factor,26
whereas a recent meta-analysis did not show any prognostic
impact.27 Our own and other studies have shown that EGFR
protein expression is associated with a favorable outcome after
treatment with EGFR TKIs in NSCLC patients.6,7,10 Thus, if
there is a relationship between short allele polymorphism and
EGFR protein expression, longer CA repeats should theoreti-
cally be associated with a better prognosis (e.g., less EGFR
protein), which was shown in the study by Dubey et al.17
Before a marker is marketed as predictive, the prog-
nostic role of the marker must be studied without including
the particular treatment for which it is “predictive.” A marker
can be prognostic (bad or good) after, for example, surgery
and predictive for a specific treatment. The most typical
example is HER2 in breast cancer, which is an unfavorable
prognostic marker in patients treated only with surgery, but a
good predictive marker for treatment with trastuzumab (Her-
ceptin).28 The prognostic role of a marker is important to take
into account when a marker is studied for its prediction of
clinical outcome after a given therapy.
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